e-ISSN 2329-0072




Early results of aortic valve replacement with Labcor biological prostheses

Andrzej Walczak, Anna Kośmider, Stanisław Ostrowski, Mirosław Bitner, Karol Bartczak, Sławomir Jander, Radosław Zwoliński, Marzanna Zielińska, Piotr Okoński, Ryszard Jaszewski

Med Sci Tech 2008; 49(4): RA223-227

ID: 881630

Available online:

Published: 2008-03-21

Introduction: Aortic valve replacement (AVR) is indicated as a standard procedure in most cases of symptomatic artic valve disease. Two different types of prostheses are commonly used; mechanical and biological ones. Biological prostheses have weak thrombogenic properties and, in most of the patients, they do not require anticoagulation. Unfortunately, bioprostheses have relatively low durability which yields with a high rate of re-do operations. Material and methods: Between 2006 and 2008, in the Department of Cardiac Surgery, Medical University of Lodz, 268 patients were operated upon due to aortic valve disease. Thirty six of them had a porcine bioprosthesis Labcor TLPB-A Supra (Labcor Laboratorios Ltda., Brazil) implanted in aortic position. In this subset of patients were 15 women and 21 men, at the mean age of 72,2±3,7 years. The age of female patients ranged from 69 to 80 years (mean 73,8±3,65) and the male patients’ age was between 65 and 76 years (mean 71±3,41). The mean Euro SCORE Risk Profile for this group was 7,07±4,37%. Results: Perioperative mortality was 8,3% (3 patients). The most frequently observed complication in the analyzed group, in early postoperative period was atrial fibrillation which occurred in 17 patients (47%). Low cardiac output syndrome and postoperative consciousness disorders were present in 11% of the patients. For small size bioprostheses of 19 and 21 mm, higher transvalvular gradients (mean and maximal) were observed. Values of indexed effective orifice area (EOAi) ranged from 0,76 cm2/m2 for 19 mm bioprosthesis to 1,0 cm2/m2 for 23 mm bioprosthesis. Conclusions: In spite of relatively high transvalvular gradients and low values of EOAi for 19 and 21 mm bioprostheses, early outcome of AVR procedure were good. The analyzed group requires further clinical and echocardiographic follow-up observation. (Clin Exp Med Lett 2008; 49(4): 223-227)

Keywords: aortic valve replacement, biological prostheses